Biotech entity
FDA is the most frequent co-covered peer, appearing in 6 of the 16 tracked stories. Negative sentiment reaches 19% here, compared with 17% across the 720-story beat baseline for the same window. The 197-day window averages about 0.6 stories each week. The busiest single day carried 2.
Last mentioned: Sep 9, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
FDA is the most frequent co-covered peer, appearing in 6 of the 16 tracked stories. Negative sentiment reaches 19% here, compared with 17% across the 720-story beat baseline for the same window. The 197-day window averages about 0.6 stories each week. The busiest single day carried 2. Source depth averages 3.6 original sources per story, versus 3.5 across the same-window beat baseline. Their average consequence score of 6 runs below the beat's 6.1 for that window. The clearest coverage concentration is fda-approval: 9 of 16 stories, with the rest divided among 2 other categories. This profile follows 16 Biotech stories mentioning Robert F. Kennedy Jr. across the period from February 25, 2026 to September 9, 2026.
Computed from the 16 stories linked to this entity, with beat comparisons drawn from all 720 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Robert F. Kennedy Jr.. Shared-story counts are live from our verified record — not editorial picks.
HHS announces permanent FDA center directors
Four senior positions filled, including permanent directors for drugs, vaccines/biologics, and tobacco products.
Trump announces Heidi Overton as FDA Commissioner nominee
President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
FDA Decision Deadline
The agency faces a deadline to approve or reject the vaccine.
FDA Advisory Panel Hearing
Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.
Advisory Panel Recommends Approval
An FDA advisory panel votes in favor of approving the vaccine.
Marty Makary resigns as FDA Commissioner
The previous FDA head leaves behind unfinished projects on ultraprocessed foods, antidepressants, and COVID-19 shots.
Tracy Beth Høeg departs CDER
Høeg says she was fired as director of the FDA's Center for Drug Evaluation and Research.
Michael Davis assumes acting CDER director
Davis steps in as acting director of CDER following Høeg's departure.
Federal Injunction
A federal judge issues a temporary block on the administration's vaccine agenda, citing public health risks.
Court Ruling
Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul.
Legal Challenge
The AAP and ACP file suit in Massachusetts federal court to block the changes.
Proposed Schedule Changes
The administration proposes sweeping changes to the national pediatric immunization schedule.
FDA Issues Refuse-to-File Letter
FDA informs Moderna it will not review the mRNA flu shot application, surprising the company after prior assurances.
FDA Accepts Application After Outcry
A little over a week later, the agency reverses its decision after Moderna commits to a confirmatory study.
Policy Shift Initiated
RFK Jr. begins implementing a new agenda for federal vaccine oversight and safety reviews.
ACIP Restructuring
HHS replaces existing ACIP members with figures aligned with the administration's views.
HHS Policy Shift
Secretary RFK Jr. issues a memo reducing universal vaccine recommendations.
Michael Davis returns to FDA as deputy director
Davis rejoins the agency after working at a nonprofit pursuing psychedelic drug development.
The FDA's new permanent CDER director is Michael Davis, whose psychiatric drug and psychedelic nonprofit background aligns with White House calls for faster psilocybin, MDMA, and LSD reviews. Vaccine and tobacco center leadership also stabilized.
Lower drug prices are being pursued through voluntary deals rather than enforceable regulation, a September 2026 report finds. For biopharma, the result is reputational pressure without legal clarity, and 'victories' that have yet to materialize.
Source: dailylocal.com · troyrecord.com
For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA.
Source: MedPage Today · Kstp Television
Biopharma's key regulator is set to change hands as Trump nominates Heidi Overton, architect of drug-pricing negotiations and vaccine-schedule revisions. Developers and investors are assessing what her confirmation means for approval timelines, pricing pressure, and regulatory predictability.
Source: nbcwashington.com · kfbk.iheart.com
The forced closure of beagle breeder Ridglan Farms and the rescue of its 475 remaining dogs intensifies bioethical scrutiny on animal testing practices, potentially disrupting preclinical supply chains and accelerating the shift toward alternative methods in drug development.
Source: chicoer.com · bostonherald.com
The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Source: kawc.org · wknofm.org
The planned shutdown of Network for Hope over pressure to retrieve organs from a living patient spotlights the fragile ethical foundation of the human tissue supply chain. Biotech companies reliant on donated organs for research and development face new regulatory uncertainty.
Senator Bill Cassidy's public denouncement of HHS Secretary Kennedy for building health policy on lies injects fresh uncertainty into the biotech and pharma industry. Vaccine research and markets face headwinds if top federal officials continue to sow distrust, potentially altering investment and development pipelines.
Source: cbsnews.com · yahoo.com
Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Source: wknofm.org · wmuk.org
After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Source: news.wjct.org · wdiy.org
A divided FDA panel backed three unapproved peptides for pharmacy compounding despite agency warnings of insufficient safety data. The vote raises concerns about political influence and the erosion of evidence-based standards in biopharmaceutical regulation.
Source: nbcdfw.com · nbcnewyork.com
The lack of a clear MAHA framework from the EPA creates uncertainty for biotech and pharma companies navigating chemical regulations, potentially affecting R&D investment, product approvals, and market positioning for bio-based alternatives.
Source: abcnews.com · durangoherald.com
HHS Secretary Kennedy warns that Chinese companies accounted for nearly half of global pharmaceutical licensing deals in 2025, prompting FDA actions to streamline early-stage trials and potentially reduce drug development times by 6 to 12 months. The shift could reshape US biotech competitiveness and investment returns.
A federal judge has issued a temporary injunction against Robert F. Kennedy Jr.’s proposed changes to national vaccine policy, citing potential risks to public health. The ruling provides a reprieve for pharmaceutical manufacturers and public health agencies while the legal merits of the administration's agenda are debated.
A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws.
Recent large-scale clinical studies are directly contradicting public health claims made by Robert F. Kennedy Jr. regarding the safety profiles of vaccines, acetaminophen, and antidepressants. These findings provide a critical scientific defense for pharmaceutical manufacturers facing increased regulatory scrutiny and litigation risks.
Robert F. Kennedy Jr. is linked from 16 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
